Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CATX

Perspective Therapeutics Inc

Dec 07 • 03:03PM ET

0.2623

Dollar change +0.0044
Percentage change 1.73	%

Healthcare • Medical Devices • USA • AMEX

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.09	Insider Own	27.54%	Shs Outstand	-	Perf Week	2.88%
Market Cap	73.61M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	203.29M	Perf Month	-2.83%
Income	-23.91M	PEG	-	EPS next Q	-0.04	Inst Own	13.04%	Short Float / Ratio	0.95% / 1.96	Perf Quarter	-31.84%
Sales	8.84M	P/S	8.33	EPS this Y	-	Inst Trans	-2.22%	Short Interest	1.93M	Perf Half Y	-50.96%
Book/sh	0.35	P/B	0.75	EPS next Y	-	ROA	-27.07%	Target Price	1.30	Perf Year	-24.66%
Cash/sh	0.06	P/C	4.09	EPS next 5Y	-	ROE	-29.53%	52W Range	0.20 - 0.73	Perf YTD	6.17%
Dividend	-	P/FCF	-	EPS past 5Y	14.18%	ROI	-23.50%	52W High	-64.05%	Beta	1.53
Dividend %	-	Quick Ratio	2.55	Sales past 5Y	-	Gross Margin	27.13%	52W Low	27.98%	ATR	0.02
Employees	-	Current Ratio	2.67	Sales Q/Q	27.26%	Oper. Margin	-346.50%	RSI (14)	50.37	Volatility	6.46% 7.14%
Optionable	No	Debt/Eq	0.03	EPS Q/Q	-29.02%	Profit Margin	-270.46%	Rel Volume	0.15	Prev Close	0.26
Shortable	Yes	LT Debt/Eq	0.03	Earnings	Nov 14 AMC	Payout	-	Avg Volume	986.92K	Price	0.26
Recom	1.00	SMA20	3.22%	SMA50	-1.66%	SMA200	-43.94%	Volume	125,364	Change	1.73%

Today 08:00AM	Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT--NET to Treat Refractory or Relapsed Neuroendocrine Tumors (GlobeNewswire)
Nov-28-23 08:00AM	Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT--NET by Clinical Collaborators in Germany (GlobeNewswire)
Nov-27-23 08:00AM	Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals (GlobeNewswire)
Nov-16-23 08:00AM	Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy (GlobeNewswire)
Nov-14-23 04:25PM	Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights (GlobeNewswire)
08:00AM	Loading…
Nov-08-23 08:00AM	Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT--NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors (GlobeNewswire)
Oct-16-23 08:00AM	Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma (GlobeNewswire)
Oct-10-23 08:00AM	Perspective Therapeutics VMT--NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium (GlobeNewswire)
Oct-05-23 04:05PM	Perspective Therapeutics Cesium-131 Featured at the American Society for Radiation Oncologys Annual Conference (GlobeNewswire)
Sep-12-23 08:00AM	Perspective Announces Presentation of Positive Early Clinical Data for VMT--NET at the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Sep-11-23 08:00AM	Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Aug-30-23 08:17AM	Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023 (GlobeNewswire)
Aug-28-23 08:00AM	Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Aug-11-23 09:15AM	Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:11AM	Perspective Therapeutics: Q2 Earnings Snapshot (AP Finance)
08:05AM	Loading…
08:05AM	Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma (GlobeNewswire)
08:00AM	Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights (GlobeNewswire)
Aug-09-23 08:05AM	Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment (GlobeNewswire)
Jun-27-23 08:00AM	Perspective Therapeutics Cesium-131 Featured at the American Brachytherapy Societys Annual Conference (GlobeNewswire)
Jun-21-23 08:00AM	Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates (GlobeNewswire)
Jun-16-23 08:00AM	Perspective Therapeutics Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Societys Annual Meeting (GlobeNewswire) +24.37%
Jun-08-23 08:00AM	Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference (GlobeNewswire)
May-28-23 06:36PM	The Best Penny Stock to Buy Now ZH vs CATX vs LMFA (InvestorPlace)
May-24-23 08:10AM	Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS) (GlobeNewswire)
May-16-23 05:02AM	Perspective Therapeutics: Fiscal Q3 Earnings Snapshot (AP Finance) -21.54%
May-15-23 08:22PM	Perspective Therapeutics Reports First Quarter Fiscal 2023 Results (GlobeNewswire)
05:35PM	Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:49PM	Perspective Therapeutics Announces Changes to the Board of Directors (GlobeNewswire)

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1998 and is headquartered in Seattle, WA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CATX

Perspective Therapeutics Inc

Upgrade your FINVIZ experience